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Equinus is the most common problem in ambulatory children with spastic cerebral
palsy (CP), which results in an unstable and inefficient gait pattern. Without proper
management at an early stage, it can evolve into permanent foot deformities that
may require multiple surgical interventions. Early therapeutic intervention to
address this problem can allow children to maintain or regain full range of motion
(ROM) and maximize functional mobility. In addition, such an intervention may
help to prevent contracture or to postpone surgical intervention. Currently, a
number of conservative interventions for managing equinus in children with CP
are available, such as bracing, stretching exercises, electrical stimulation, and
casts/serial casting.
1-3 Botulinum toxin type A (BTX-A) injection into triceps surae
muscles has been considered an effective therapeutic approach. Reduction of tone
and an increase in ROM at the ankle joint and an improvement of gait pattern
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Purpose: The purpose of this paper is to test the hypothesis that combination therapy
of serial cast and botulinum toxin type A (BTX-A) injection can further enhance
the effects of a BTX-A injection in ambulant children with cerebral palsy (CP)
who have an equinus foot. Materials and Methods: Children in group A (30 legs
of 21 children) received a serial casting application after an injection of BTX-A,
and children in group B (25 legs of 17 children) received only a BTX-A injection.
Assessments were performed before the intervention and 1 month after the inter-
vention. Results: After the intervention, there were significant improvements in
tone, dynamic spasticity, and passive range of motion (ROM) in both groups.
However, the changes were greater in group A than in group B. Dimension D
(standing) in Gross Motor Function Measure (GMFM)-66 was significantly
improved in group A but not in group B. On the other hand, there were no signifi-
cant changes in di-mension E (walking, running, jumping) in GMFM-66 in either
group. Conclusion: The results of our study suggest that a serial casting application
after BTX-A injection can enhance the benefits of BTX-A injection in children
with cerebral palsy.
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with a BTX-A injection have been demonstrated in litera-
ture.
2,4-7 
The immobilization of a muscle in a lengthened position
for a prolonged period of time gradually increases in both
length and the number of sarcomeres in the target muscle.
8
According to a previous study,
9 a spastic muscle responds
to progressive casting by increasing its length in the same
way that a normal muscle responds. Thus, casting in child-
ren with CP has been used to increase ROM
10 through this
physiological adaptation to prolonged stretching. A signifi-
cant increase in ROM and tone reductions with casts in
children with CP were reported in previous studies.
1,2,11-14
Compared to a single fixed cast, serial casting involves the
removal and reapplication of a cast at certain intervals. Each
time the cast is changed, the ankle is positioned into greater
dorsiflexion in order to stretch the calf muscle progressi-
vely up to the desired ROM at the ankle joint. When a
mild fixed ankle plantarflexor contracture is present, serial
casting seems to be effective in lengthening the triceps
surae musculature. 
Both BTX-A injection and casting seem to be effective
for reducing tone and improving ROM. The effects of both
modalities for managing equinus in these children were
compared to those in previous studies. Various results show-
ing similar efficacy for both modalities
15 or favoring BTX-
A injecton
2 or favoring casting
13,16 were reported in previous
studies. Moreover, only a few reports show the effects of
the combined therapy of BTX-A injection and casting for
managing equinus in these children.
13,14,16-18 While in some
studies combined therapy resulted in better outcomes than
those of BTX-A alone,
13,16,17 better outcomes were reported
with serial casting alone than the combined therapy of
BTX-A and serial casting.
14 Therefore, the objective of the
present study was to determine whether the combined
therapy of serial casting and BTX-A injection can further
enhance the effects of the BTX-A injection in ambulant
children with CP who have equinus foot. 
Participants
Among children with spastic CP, the children who met the
following inclusion criteria were selected as subjects for
this study: 1) able to walk independently without aids, 2)
had an equinus foot with mild shortening of the calf
muscle that does not allow the ankle with knee extended to
dorsiflex more than 10
O, 3) had not yet developed joint or
bone deformities, and 4) had not had orthopaedic surgery
before. In total, 38 children were recruited as participants
for this study. According to each parent’s willingness to
have his or her child undergo serial casting, serial casting
was applied to 30 legs of 21 children after BTX-A (group
A). BTX-A alone was administered to 25 legs of 17 children
(group B). 
This study was conducted with the approval of our Insti-
tutional Review Board (4-2008-0456).
Design and procedures
The muscle tone of the ankle plantar flexor with the knee
in flexion and extension was assessed with the modified
Ashworth scale (MAS), which is a 6-point rating scale
from 0 to 4 used to gauge muscle tone.
19 For the conve-
nience of statistical analysis, MAS 1 +  was converted to 2.
Likewise, MAS 2, 3, and 4 were converted into 3, 4 and 5,
respectively. In addition, the modified Tardieu scale (MTS)
was used to assess the ankle plantar flexor with the knee in
flexion and extension.
20 Two levels of passive ROMs were
measured, referring to R1 and R2 angles. R2 refers to total
passive ROM into ankle dorsiflexion, while R1 refers to
the point in the ROM where a ‘catch’ was felt during a
quick stretch of the ankle plantarflexor. The ankle ROM
angle in MTS was measured by manual goniometry with
the “neutral-null” method (dorsiflexion angle over the
neutral position was counted in positive degrees, under the
neutral in negative degrees). Gross Motor Function Measure
(GMFM)-66, which has excellent reliability (ICC = 0.99)
and is responsive to change, was used to assess motor func-
tion.
21 It is divided into five dimensions of motor function
(A: lying and rolling, B: sitting, C: crawling and kneeling,
D: standing, and E: walking, running, jumping).
22 All of
the children were able to walk independently, and therefore
dimensions D and E in GMFM-66 were chosen as functio-
nal measures for this study.
23 The assessment was perform-
ed by a physical therapist for GMFM scoring and by a
physician for other outcome measures who were unaware
of the type of intervention that the child had received. All
of the parameters were recorded the before intervention
and at 1 month after the intervention.
Interventions 
BTX-A was injected into both the medial and lateral heads
of spastic gastrocnemius muscle. Doses selected for BTX-
A injection were individualized on the basis of body weight,
severity of spasticity, and movement pattern as established
by our empirical methods. Before injection, a lidocaine-
based local anesthetic, EMLA cream (Astra, Kings Langley,
UK), was applied to the skin and a sample of BTX-A
(Botox
®; Allergan, Inc, Irvine, CA, USA) diluted with 2
mL of 0.9% saline was injected into the target muscles
under the guidance of ultrasonography.
Serial casting consisted of short leg casts applied in prone
position with the knee flexed to 90
O and the ankle dorsi-
flexed to maximal attainable dorsiflexion and held in the
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neutral hind foot position. Three consecutive casts were
applied for 1 week each with a progressively increasing
amount of ankle dorsiflexion to stretch the calf muscle.
Ankle-foot orthosis was applied to the children in group B
immediately after the injection and after the completion of
serial casting in group A.
The intensity and frequency of physical and occupatio-
nal therapy given to the children after the intervention was
the same for both groups. Both groups underwent 30
minutes of physical therapy and 30 minutes of occupa-
tional therapy per day six times a week. Physical and
occupational therapy comprised play-based activities based
on the neurodevelopmental techniques. Physical therapy
focused to improve performance in and gain independence
with such tasks as making transfers, stretching, bed mobil-
ity, and safe ambulation. Occupational therapy focused on
tasks such as weight bearing on the arm, reaching, grasp-
ing, holding, manipulating an object, fine motor hand
skills, and activities of daily living that were age appropriate.
Statistical analysis
SAS version 9.1.3 was used for statistical analyses. Bet-
ween groups A and B, the numerical parameters were
compared using an independent t-test, and the nominal data
were compared using a Chi-square test. In each group, the
parameters before and after treatment were compared using
a paired t-test. Statistical significance was defined as a p-
value of < 0.05.
The characteristics of participants and the values of para-
meters assessed before the intervention are described in
Table 1. The mean age of the children was 4.6 years (range
2.3 to 8.3 years) in group A and 4.7 years (range 3.6 to 7.8
years) in group B. There were no significant differences in
age, body weight, the distributions of sex, and the functio-
nal levels based on the Gross Motor Function Classification
System (GMFCS) between the groups (p > 0.05) (Table 1).
The mean dose of BTX-A injected into each gastrocne-
mius was 4.9 (range 4.0 to 6.0) units/kg and 5.0 (range 4.5
to 6) units/kg in groups A and B, respectively. There was
no significant difference in the doses of BTX-A between
the groups.
In addition, the baseline measurements of the MAS and
the R1 and R2 angles in the MTS were not significantly
different between the groups (p > 0.05). The scores of di-
mension D and E in GMFM-66 in group A were not signifi-
cantly different from those in group B (p> 0.05) (Table 1).
The MAS of the ankle joint with knee flexion and exten-
sion was significantly reduced in both groups after inter-
vention (p < 0.05). The MAS at the ankle joint with knee
flexion after intervention was significantly lower in group
A than in group B (P < 0.05), whereas the MAS was not
significantly different between the two groups at the ankle
joint with knee extension. Significant differences in the
changes of MAS between the two groups were noted at the
ankle joint only with knee flexion, but not with knee exten-
sion (Table 2).
R1 angles of MTS at the ankle joint with knee flexion
and extension significantly improved after treatment in
both groups (p < 0.05). The R1 angles in group A were
significantly higher at the ankle joint with knee flexion and
extension than those in group B (p < 0.05). Furthermore,
the changes were greater in group A than in group B at the
ankle joint with knee flexion and extension (p < 0.05)
(Table 2).
The R2 angles of MTS at the ankle joint with knee flexion
and extension significantly increased after intervention in
both groups (p < 0.05). The changes at both knee flexion
and extension were significantly greater in group A than in
group B (p< 0.05) (Table 2).
In group A, there was significant improvement in dimen-
sion D of GMFM-66 after treatment (p < 0.05), but not in
dimension E of GMFM-66 (p > 0.05). In group B, there
were no significant changes in dimension D and E of
GMFM-66 after treatment (p> 0.05) (Table 3).
RESULTS
Table 1.Background Characteristics of the Participants
Group A Group B 
Age (mean ± SD, yrs) 4.6 ± 1.5 4.7 ± 1.0
Sex (F / M, n) 9 / 12 5 / 12
Weight (mean ± SD, kg) 17.2 ± 3.2 16.2 ± 3.3
Type of cerebral palsy
(diplegia / hemiplegia / monoplegia / triplegia, n) 13 / 5 / 1 / 2 10 / 4 / 1 / 2
GMFCS (I / II / III, n) 13 / 5 / 3 10 / 3 / 4
Dimension D in GMFM-66 (mean ± SD) 75.34 ± 29.58 72.44 ± 23.91
Dimension E in GMFM-66 (mean ± SD) 65.38 ± 34.50 60.53 ± 32.71
GMFCS, Gross Motor Function Classification System; GMFM, Gross Motor Function Measure.Eun Sook Park, et al.
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An equinus foot in children with spastic CP is caused by
spasticity or shortening of the gastocnemius-soleus muscle
complex or a combination of these two components. Initi-
ally, it appears to be a dynamic phenomenon, secondary to
a central nervous system lesion. As the child grows, the
progressive shortening of the calf muscles secondary to
spasticity develop to such a significant degree that the con-
tracture may require surgical lengthening of the muscle or
tendon unit. For dynamic equinus, a BTX-A injection into
the calf muscles has been considered an effective form of
management.
2,4,5 For such cases, BTX injection into the
triceps surae muscles results in significant tone reduction
and an increase in ROM has been noted in literature.
5-7 Our
present study confirms the findings of previous reports on
the efficacy of BTX-A injections in the treatment of equi-
nus in children with CP.
Since BTX-A injection works mainly on spasticity, the
effect of BTX-A injection is limited when there is muscle
contracture. On the other hand, casting works mainly on
muscle contracture, and therefore, cast application might
be helpful for gaining additional ROM in cases in which
there is muscle contracture.
13,24 In particular, two kinds of
cast application were used in the literature for managing
equinus in the children with CP. A single fixed cast is ap-
plied at the neutral position of the ankle joint for a certain
period of time, while serial cast applications involve remo-
vals and reapplications at certain intervals to ensure more
ankle dorsiflexion at each cast. In five previous studies
showing the effects of combined therapy of cast and BTX-
A, a single fixed cast was used in two reports,
16,17 while
serial casts were used in three studies.
13,14,18 In the reports
using serial casts in conjunction with BTX-A, more mark-
ed improvement in passive ankle dorsiflexion was achieved
in 2 reports,
13,14 and faster improvements in ROM
18 were
achieved, compared to treatment with BTX-A alone. In
reports using a single fixed cast, the improvement in ROM
was greater after treatment with combined therapy than
BTX-A alone.
16 On the other hand, the addition of a fixed
cast to BTX-A did not result in any significant gains in the
passive ROM of the ankle joint in the report by Bottos, et
al.
17 Since the effects of serial casting on passive ROM
have not yet been studied, in comparison with a single fixed
cast for treating equinus in these children, it is not yet
known whether serial casts or fixed casts are more effec-
tive.
25 However, theoretically, the serial cast may be more
effective in lengthening the shortened musculature than a
single fixed cast. Additional gains in the ROM in the group
receiving both BTX-A and serial casting in our study likely
support the hypothesis that serial casting is an effective
DISCUSSION
Table 2.Changes after Interventions
Parameters
Group A  Group B 
Pretreatment Post treatment Change Pretreatment Post treatment Change
with knee flexed
MAS 2.7 ± 0.8 1.5 ± 0.7*
� - 1.1 ± 0.8
� 2.5 ± 0.8 2.0 ± 0.6* - 0.6 ± 0.7 
R1 angle in 
- 11.33 ± 14.02 3.67 ± 8.40*
� 15.00 ± 12.32




O) 12.00 ± 10.72 21.17 ± 9.80* 9.17 ± 8.82
� 16.60 ± 6.57 19.20 ± 8.86* 2.60 ± 6.14
with knee extended
MAS  2.9 ± 0.8 2.0 ± 0.6* - 1.0 ± 0.9 3.2 ± 0.7 2.3 ± 0.7* - 1.0 ± 0.7
R1 angle in  
- 20.67 ± 10.96 - 5.33 ± 8.70*
� 15.33 ± 12.17




O) - 1.17 ± 11.50 9.83 ± 9.51* 11.00 ± 9.77
� 2.20 ± 4.58 7.20 ± 6.30* 5.00 ± 6.12
MAS, modified Ashworth scale; MTS, modified Tardieu scale; ROM, range of motion.
Values are mean ±SD.
*p< 0.05 (pretreatment versus post treatment).
�p< 0.05 (between groups).
Table 3.Changes in Gross Motor Function Measure-66
Parameters
Group A  Group B 
Pre-treatment Post-treatment Change Pre-treatment Post-treatment Change
Dimension D 75.34 ± 29.58 79.49 ± 26.60* 4.15 ± 5.70 72.44 ± 23.91 73.50 ± 19.32 1.06 ± 9.11
Dimension E 65.38 ± 34.50 65.60 ± 32.96 0.21 ± 3.30 60.53 ± 32.71 60.42 ± 31.37 - 0.12 ± 3.33
Values are mean ±SD.
*p< 0.05 (pretreatment versus post treatment).therapeutic approach for improving ankle passive ROM.
On the other hand, in terms of tone changes, two reports
revealed better responses in tone reduction with combined
therapy of a single fixed cast and BTX-A, compared to
BTX-A alone.
16,17 Of the two reports using serial casting
applications, changes in tone were described only in the
report by Kay, et al.,
14 in which serial casting alone led to
better responses compared to combined therapy of serial
casting and BTX-A. Despite the results of their study, they
suggested that the benefits of adding BTX-A injection to
serial casting on maximizing the tolerance of the casting
may outweigh the risk of early recurrence of spasticity in
patients with more spasticity or dystonia. These previous
studies seem likely to support that combined therapy with
BTX-A and cast application benefits tone reduction. The
present study showed that the addition of serial casting to
BTX-A injection can result in further benefits in tone re-
duction compared to BTX-A alone. Because we did not
evaluate the sample size, we also calculated the observed
statistical power. The observed power of the change in R1
and R2 angles of MTS at the ankle joint with extension
was 0.72 and 0.79, respectively. We thought that more cases
would be needed for a larger statistical power. Further
study will be needed.
In addition, changes in passive and dynamic ankle mo-
tion with combination therapy seem to result in significant
improvement in dimension D (standing) in GMFM-66.
However, there was no significant change in dimension E
(walking) in GMFM-66. Activities in dimension E are more
difficult to achieve than those of dimension D. Hence, seve-
ral exercises are required to produce any significant changes
in dimension E. This might explain why significant change
was achieved only in dimension D, but not dimension E in
our short-term follow-up. In a previous study,
17 the GMFM-
66 (standing and walking scores) scores significantly
improved 4 months after the intervention of BTX-A with a
single cast; therefore, we think that dimension E (walking)
may improve in the long-term assessment. 
As for the longevity of the effects of casting application
for the equinus of children with CP, some studies revealed
long-lasting changes throughout the 12-month follow-up
period,
14,16 while others showed much shorter-lasting ef-
fects.
2,3 A single fixed cast application in conjunction with
a BTX-A injection, in comparison with BTX-A alone,
resulted in more enduring effects in the reports by Bottos,
et al.
17 and Ackman, et al.
16 In contrast, the addition of
BTX to serial casting revealed shorter-term effects, com-
pared to serial casting alone, in cases of fixed contracture
in the report by Kay, et al.
14 With our short-term follow-up
study, we could not determine the time when the effects of
the interventions started to deteriorate because the follow-
up periods in our cases varied. A long-term follow up study
is needed to find out whether additional serial casting
applications after BTX-A injection can lead to more func-
tional benefits and more enduring results.
Our study was limited in that we did not perform formal
reliability testing for the assessments measured in this
study. However, all range of motion and spasticity measure-
ments were performed with the use of consistent techni-
ques by the same physician (W.H.C.), and the GMFM
tests were performed with the use of a standardized proce-
dure and scoring
22 by the same physical therapist (Y.L.)
who had more than 5 years of experience. In addition, a
previous report revealed high inter-rater reliability, ranging
from 0.85 to 0.96 in these measures assessing the outcomes
of the interventions to treat equinus in the children with
CP. In addition, they concluded that, with regard to accep-
tability, practicability, and responsiveness, these tests could
be effectively performed on these children who have equi-
nus deformity.
26 As a result, we believe that the changes
observed in our study with these assessments are accep-
table and reliable.
In conclusion, significant improvements in tone and ROM
with BTX-A alone suggest that BTX-A injection may be
effective in treating a spastic equinus foot in children with
CP. On the other hand, children who underwent both serial
casting and BTX-A injection showed more marked changes
in tone reduction, dynamic ankle motion, and passive
ROM. In addition, dimension D in GMFM-66 significan-
tly improved in the combination therapy group. These find-
ings suggest that combination therapy of BTX-A and serial
casting is a promising therapeutic strategy for enhancing
the benefits of BTX-A injection in children with CP. How-
ever, a long-term follow up study is needed to find out
whether additional serial casting applications after BTX-A
injection can lead to more functional benefits and more
enduring results.
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